Lisata Therapeutics financials
$1.47−2.00%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 |
|---|---|---|---|---|
| Revenue | $170.0K | $1.0M | $0.00 | $0.00 |
| Gross profit | $170.0K | $1.0M | $0.00 | $0.00 |
| Gross margin | 100.0% | 100.0% | — | — |
| Operating income | -$18.2M | -$22.4M | -$25.7M | -$57.6M |
| Net income | -$16.6M | -$20.0M | -$20.8M | -$54.2M |
| Net margin | −9756.5% | −1998.5% | — | — |
| Diluted EPS | $-1.91 | $-2.40 | $-2.58 | $-10.47 |
| EBITDA | -$18.1M | -$22.2M | -$25.5M | -$57.5M |
| Operating cash flow | -$15.9M | -$19.4M | -$20.0M | -$21.2M |
| Free cash flow | -$16.0M | -$19.4M | -$20.0M | -$21.5M |
| Diluted shares | 8.7M | 8.3M | 8.1M | 5.2M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|
| Cash & equivalents | $16.0M | $16.2M | $22.6M | $32.2M |
| Short-term investments | $0.00 | $15.0M | $27.9M | $37.1M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $17.7M | $35.0M | $54.7M | $73.0M |
| Total liabilities | $3.1M | $5.7M | $6.8M | $6.7M |
| Shareholders' equity | $14.6M | $29.3M | $47.9M | $66.3M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology